Phase II Study of Brigatinib for ALK-positive advanced non-small cell lung cancer with brain metastases (BRAVES study(LOGIK2201))

未提供0 个研究点目标入组 22 人开始时间: 2023年11月13日最近更新: 2025年5月27日

试验速览

暂无简介。

•A histologically or cytologically confirmed diagnosis of non-small cell lung cancer.
•Stage IV, postoperative recurrence or recurrence after radical irradiation of the trunk more than 24 weeks after the last irradiation date.
•The patient has been diagnosed as ALK fusion-positive by the companion diagnostic agent brigatinib.
•No history of ALK inhibitor administration (patients who received alectinib as adjuvant therapy can be enrolled if they have not had a recurrence during alectinib treatment and more than 180 days have passed since the last alectinib administration).
•The applicant is at least 18 years of age on the date consent is obtained.
•Performance status (PS) is 0 to 2 according to ECOG criteria (PS must be documented in the medical record).
•Brain metastases with the longest diameter more than twice the slice width and more than 5 mm on head MRI within 28 days prior to registration. The presence or absence of brain metastasis symptoms is not required.
•The presence or absence of measurable lesions other than brain metastases is not required.
•No severe impairment of major organs (bone marrow, heart, lungs, liver, kidney, etc.)
•Patients who can take oral medications.
•Patients expected to survive at least 3 months.
•If the prior treatments or procedures were performed prior to enrollment, the specified period of time since completion has elapsed.
•Written consent to participate in this study has been obtained from the patient.

•Brain metastases requiring urgent radiotherapy or surgical resection.
•Patients with interstitial lung disease (drug-induced lung injury and radiation pneumonitis are eligible for registration if they have improved).
•Symptomatic congestive heart failure, unstable angina, myocardial infarction, or symptomatic cerebrovascular disease within 3 months prior to enrollment.
•Poorly controlled hypertension.
•Patients with poorly controlled diabetes mellitus.
•Has an infection requiring systemic treatment.
•Have active hepatitis B or hepatitis C
•Active overlapping carcinoma.
•Women who are pregnant. Lactating women. Women who are unwilling to use contraception during this study.
•Men who are unwilling to use contraception during this study.
•The patient has a psychiatric disorder or psychiatric symptoms that interfere with his/her daily life and makes participation in the study difficult.
•Other patients who are deemed inappropriate for the conduct of this study by the physician in charge, etc.

Response rate in brain metastases (modified RECIST criteria)

未报告次要终点

发起方

未提供